{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,28]],"date-time":"2026-07-28T06:00:04Z","timestamp":1785218404027,"version":"3.55.0"},"reference-count":31,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,7,28]],"date-time":"2026-07-28T00:00:00Z","timestamp":1785196800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>In this study, we used Mendelian randomization analysis to explore the causal relationships between drug targets and cutaneous melanoma (CM) and subsequently screened for new drug targets for CM. In addition, we verified whether targeted drugs could inhibit the development of CM in CM cells by suppressing the expression of target genes.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>The eQTL data of 2,664 drug target genes (exposures) were sourced from the eQTLGen database. The GWAS summary data for CM (outcome) were obtained from the UK Biobank and FinnGen databases. The inverse-variance weighted (IVW) model was used as the primary analytical method. For the cell experiments, we first conducted RT-PCR and western blot analyses in three CM cell lines to validate the expression of LTA4H. LTA4H was subsequently knocked down and overexpressed in CM cell lines, and the proliferation, migration, invasion, and apoptosis of CM cells were evaluated. Finally, bestatin was used to stimulate CM cells to examine its effect on their malignant functions.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>MR, GEO2R, and PheWAS analyses revealed that high expression of LTA4H can promote the development of CM. In cell experiments, compared with normal fibroblasts, melanoma cells highly expressed LTA4H. Moreover, after LTA4H was knocked down in SK-MEL-28 cells, their malignant functions decreased. After LTA4H was overexpressed in A-375 cells, the degree of malignancy increased. Finally, bestatin inhibited the malignancy of A-375 cells through the regulation of LTA4H.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>In this study, MR analysis revealed that high expression of LTA4H can promote the occurrence of CM. In addition, the results of the cell experiments revealed that bestatin can inhibit the development of melanoma cells by reducing the expression of LTA4H.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fimmu.2026.1901844","type":"journal-article","created":{"date-parts":[[2026,7,28]],"date-time":"2026-07-28T05:34:12Z","timestamp":1785216852000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Bestatin inhibits the development of cutaneous melanoma by inhibiting the expression of LTA4H"],"prefix":"10.3389","volume":"17","author":[{"given":"Pan","family":"Luo","sequence":"first","affiliation":[{"name":"Department of Plastic Surgery, Beijing Chaoyang Hospital Affiliated to Capital Medical University","place":["Beijing, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mingyi","family":"Yang","sequence":"additional","affiliation":[{"name":"Department of Joint Surgery, HongHui Hospital, Xi\u2019an Jiaotong University","place":["Xi\u2019an, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yani","family":"Su","sequence":"additional","affiliation":[{"name":"Department of Radiotherapy, Tangdu Hospital, The Fourth Military Medical University","place":["Xi\u2019an, Shaanxi, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pengfei","family":"Wen","sequence":"additional","affiliation":[{"name":"Department of Joint Surgery, HongHui Hospital, Xi\u2019an Jiaotong University","place":["Xi\u2019an, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiqin","family":"Lu","sequence":"additional","affiliation":[{"name":"Department of Hand Surgery, Honghui Hospital, Xi\u2019an Jiaotong University","place":["Xi\u2019an, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,7,28]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"485","DOI":"10.1016\/s0140-6736(23)00821-8","article-title":"Cutaneous melanoma","volume":"402","author":"Long","year":"2023","journal-title":"Lancet (London England)"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1016\/j.asjsur.2023.08.167","article-title":"Statin medication and Malignant melanoma of skin: A Mendelian randomization study","volume":"46","author":"Zhi","year":"2023","journal-title":"Asian J Surg"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1016\/j.det.2025.03.005","article-title":"Trends in melanoma incidence and mortality","volume":"43","author":"Shah","year":"2025","journal-title":"Dermatologic Clinics"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1002\/jso.27685","article-title":"Characteristics and variations in young adults with cutaneous melanoma: A national cancer database analysis","volume":"129","author":"Greene","year":"2024","journal-title":"J Surg Oncol"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1016\/j.det.2025.03.001","article-title":"Risk factors for the development of primary cutaneous melanoma","volume":"43","author":"Sejdiu","year":"2025","journal-title":"Dermatologic Clinics"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.3390\/ijms242115881","article-title":"Cutaneous melanoma: A review of multifactorial pathogenesis, immunohistochemistry, and emerging biomarkers for early detection and management","volume":"24","author":"Gosman","year":"2023","journal-title":"Int J Mol Sci"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra2034861","article-title":"Recent advances in the treatment of melanoma","volume":"384","author":"Curti","year":"2021","journal-title":"N Engl J Med"},{"key":"B8","doi-asserted-by":"publisher","first-page":"54","DOI":"10.5334\/gh.1438","article-title":"Mendelian randomisation: Concepts, opportunities, challenges, and future directions","volume":"20","author":"de Ruiter","year":"2025","journal-title":"Global Heart"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.k601","article-title":"Reading Mendelian randomisation studies: A guide, glossary, and checklist for clinicians","volume":"362","author":"Davies","year":"2018","journal-title":"BMJ (Clinical Res Ed)"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1681\/asn.2016010098","article-title":"Mendelian randomization as an approach to assess causality using observational data","volume":"27","author":"Sekula","year":"2016","journal-title":"J Am Soc Nephrol JASN"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.aag1166","article-title":"The druggable genome and support for target identification and validation in drug development","volume":"9","author":"Finan","year":"2017","journal-title":"Sci Transl Med"},{"key":"B12","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1186\/s12967-024-06027-4","article-title":"Association of genetically proxied cancer-targeted drugs with cardiovascular diseases through Mendelian randomization analysis","volume":"23","author":"Fang","year":"2025","journal-title":"J Transl Med"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1097\/js9.0000000000001514","article-title":"Association of glucagon-like peptide-1 receptor agonists with risk of cancers-evidence from a drug target Mendelian randomization and clinical trials","volume":"110","author":"Sun","year":"2024","journal-title":"Int J Surg (London England)"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1093\/brain\/awad070","article-title":"Potential drug targets for multiple sclerosis identified through Mendelian randomization analysis","volume":"146","author":"Lin","year":"2023","journal-title":"Brain A J Neurol"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1016\/j.ebiom.2023.104494","article-title":"Therapeutic targets for inflammatory bowel disease: Proteome-wide Mendelian randomization and colocalization analyses","volume":"89","author":"Chen","year":"2023","journal-title":"EBioMedicine"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1016\/j.ebiom.2022.104199","article-title":"Genetic insights into therapeutic targets for aortic aneurysms: A Mendelian randomization study","volume":"83","author":"Chen","year":"2022","journal-title":"EBioMedicine"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1038\/s41588-021-00913-z","article-title":"Large-scale cis- and trans-eqtl analyses identify thousands of genetic loci and polygenic scores that regulate blood gene expression","volume":"53","author":"V\u00f5sa","year":"2021","journal-title":"Nat Genet"},{"key":"B18","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1038\/nature15393","article-title":"A global reference for human genetic variation","volume":"526","author":"Auton","year":"2015","journal-title":"Nature"},{"key":"B19","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1007\/978-1-4939-3578-9_5","article-title":"The gene expression omnibus database","volume":"1418","author":"Clough","year":"2016","journal-title":"Methods Mol Biol (Clifton NJ)"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0010770","article-title":"Integrative genome comparison of primary and metastatic melanomas","volume":"5","author":"Kabbarah","year":"2010","journal-title":"PloS One"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1038\/s41588-020-0622-5","article-title":"Exploring and visualizing large-scale genetic associations by using Pheweb","volume":"52","author":"Gagliano Taliun","year":"2020","journal-title":"Nat Genet"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-021-03855-y","article-title":"Rare variant contribution to human disease in 281,104 UK Biobank exomes","volume":"597","author":"Wang","year":"2021","journal-title":"Nature"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1016\/j.xcrm.2025.102000","article-title":"Lta4h improves the tumor microenvironment and prevents HCC progression via targeting the Hnrnpa1\/Ltbp1\/Tgf-B axis","volume":"6","author":"Yang","year":"2025","journal-title":"Cell Rep Med"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1172\/jci97945","article-title":"Leukotriene biosynthetic enzymes as therapeutic targets","volume":"128","author":"Haeggstr\u00f6m","year":"2018","journal-title":"J Clin Invest"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1126\/science.1190594","article-title":"A critical role for Lta4h in limiting chronic pulmonary neutrophilic inflammation","volume":"330","author":"Snelgrove","year":"2010","journal-title":"Sci (New York NY)"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1038\/nrd.2015.4","article-title":"G protein-coupled receptors as targets for anti-diabetic therapeutics","volume":"15","author":"Oh","year":"2016","journal-title":"Nat Rev Drug Discov"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1093\/carcin\/bgx049","article-title":"Lta4h regulates cell cycle and skin carcinogenesis","volume":"38","author":"Oi","year":"2017","journal-title":"Carcinogenesis"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.2174\/092986711794940879","article-title":"Progress in the development of bestatin analogues as aminopeptidases inhibitors","volume":"18","author":"Chen","year":"2011","journal-title":"Curr Med Chem"},{"key":"B29","doi-asserted-by":"publisher","first-page":"2699","DOI":"10.1016\/j.jid.2021.03.032","article-title":"Bestatin cream impairs solar simulated light\u2013driven skin inflammation and skin carcinogenesis in mice","volume":"141","author":"Zhao","year":"2021","journal-title":"J Invest Dermatol"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1002\/jcb.25407","article-title":"Resveratrol increases anti-proliferative activity of bestatin through downregulating P-glycoprotein expression via inhibiting PI3K\/Akt\/mTOR pathway in K562\/ADR cells","volume":"117","author":"Wang","year":"2016","journal-title":"J Cell Biochem"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1016\/j.ebiom.2019.05.008","article-title":"Inhibition of Lta4h by bestatin in human and mouse colorectal cancer","volume":"44","author":"Zhao","year":"2019","journal-title":"EBioMedicine"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1901844\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,28]],"date-time":"2026-07-28T05:34:13Z","timestamp":1785216853000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1901844\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,28]]},"references-count":31,"alternative-id":["10.3389\/fimmu.2026.1901844"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2026.1901844","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,28]]},"article-number":"1901844"}}